AC Immune

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizations Repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titers ACI-7104.056 is well tolerated with no safety issues reported to date. 2 April 2025 -- Lausanne, Switzerland --...

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track designation granted in July for ACI-35.030 (now “JNJ-2056”) for AD. 17 September 2024 -- Lausanne, Switzerland -- AC Immune SA, a clinical-stage biopharmaceutical company pioneering...
EPFL Innovation Park-Building B 1015 Lausanne / Switzerland

+41 21 345 91 21